{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T22:24:41Z","timestamp":1767219881171,"version":"3.48.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.7759\/cureus.100519","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T22:22:25Z","timestamp":1767219745000},"source":"Crossref","is-referenced-by-count":0,"title":["A Pilot Trial of Two-Fraction Stereotactic Body Radiation Therapy for Localized Prostate Cancer"],"prefix":"10.7759","author":[{"given":"Xinglei","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay C","family":"Shiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Prostate cancer (version 2.2025). (2025). Accessed. July 7, 2025: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As N","year":"2024","unstructured":"van As N, Griffin C, Tree A, et al.. Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer. N Engl J Med. 2024, 391:1413-25. 10.1056\/NEJMoa2403365","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2020.10.009","article-title":"HDR brachytherapy as monotherapy for prostate cancer: a systematic review with meta-analysis","volume":"20","author":"Viani GA","year":"2021","unstructured":"Viani GA, Arruda CV, Assis Pellizzon AC, De Fendi LI. HDR brachytherapy as monotherapy for prostate cancer: a systematic review with meta-analysis. Brachytherapy. 2021, 20:307-14. 10.1016\/j.brachy.2020.10.009","journal-title":"Brachytherapy"},{"key":"ref4","article-title":"Gleason score","author":"Munjal A","year":"2023","unstructured":"Munjal A, Leslie SW. Gleason score. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach M 3rd","year":"2006","unstructured":"Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006, 65:965-74. 10.1016\/j.ijrobp.2006.04.029","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref6","unstructured":"Microsoft Excel. (2024). https.\/\/office.microsoft.com\/excel."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia","volume":"148","author":"Barry MJ","year":"1992","unstructured":"Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992, 148:1549-57. 10.1016\/s0022-5347(17)36966-5","journal-title":"J Urol"},{"key":"ref8","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. (2017). https.\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.12.015","article-title":"Two-fraction versus five-fraction stereotactic body radiotherapy for intermediate-risk prostate cancer: the toffee meta-analysis of individual patient data from four prospective trials","volume":"8","author":"Udovicich C","year":"2025","unstructured":"Udovicich C, Cheung P, Chu W, et al.. Two-fraction versus five-fraction stereotactic body radiotherapy for intermediate-risk prostate cancer: the toffee meta-analysis of individual patient data from four prospective trials. Eur Urol Oncol. 2025, 8:763-73. 10.1016\/j.euo.2024.12.015","journal-title":"Eur Urol Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.06.038","article-title":"Acute toxicity and early prostate specific antigen response after two-fraction stereotactic radiation therapy for localized prostate cancer using peri-rectal spacing-initial report of the SABR-Dual trial","volume":"120","author":"Fredman E","year":"2024","unstructured":"Fredman E, Moore A, Icht O, et al.. Acute toxicity and early prostate specific antigen response after two-fraction stereotactic radiation therapy for localized prostate cancer using peri-rectal spacing-initial report of the SABR-Dual trial. Int J Radiat Oncol Biol Phys. 2024, 120:1404-9. 10.1016\/j.ijrobp.2024.06.038","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16112073","article-title":"Stereotactic body radiotherapy (SBRT) to localised prostate cancer in the era of MRI-guided adaptive radiotherapy: doses delivered in the HERMES trial comparing two- and five-fraction treatments","volume":"16","author":"Westley R","year":"2024","unstructured":"Westley R, Casey F, Mitchell A, et al.. Stereotactic body radiotherapy (SBRT) to localised prostate cancer in the era of MRI-guided adaptive radiotherapy: doses delivered in the HERMES trial comparing two- and five-fraction treatments. Cancers (Basel). 2024, 16:10.3390\/cancers16112073","journal-title":"Cancers (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11430-z","article-title":"A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT)","volume":"23","author":"Wolfe S","year":"2023","unstructured":"Wolfe S, Diven MA, Marciscano AE, et al.. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT). BMC Cancer. 2023, 23:923. 10.1186\/s12885-023-11430-z","journal-title":"BMC Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/432302-a-pilot-trial-of-two-fraction-stereotactic-body-radiation-therapy-for-localized-prostate-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T22:22:26Z","timestamp":1767219746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/432302-a-pilot-trial-of-two-fraction-stereotactic-body-radiation-therapy-for-localized-prostate-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.100519","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,31]]}}}